RU2197457C1 - High-tritium-labeled n-methyl-n-2-propinylbenzylamine - Google Patents

Abstract

FIELD: biologically active compounds. SUBSTANCE: invention provides novel high-tritium-labeled analog of physiologically active compounds, namely N- methyl-N-2- propinylbenzylamine of formula I:

(I). Novel compound is prepared by treating compound I with solution of tritium water in dioxane and triethylamine under tritium atmosphere and in presence of Pd/BaSO₄ at room temperature. EFFECT: extended choice of biologically active compounds.

Description

 The invention relates to organic chemistry and may find application in biology and in medicine.

Данное соединение, получившее наименование "паргилин", является одним из сильнейших антигипертензивных препаратов (Y.Mitchell//Experientia. V.28, Р. 298).Known N-methyl-N-2-propynylbenzylamine of the formula I:

This compound, called "pargyline", is one of the strongest antihypertensive drugs (Y. Mitchell // Experientia. V.28, P. 298).

 However, a tritium-labeled analog of this physiologically active compound is not described.

 The technical result achieved by the implementation of the present invention is to expand the range of tritium-labeled analogues of physiologically active compounds.

 The specified technical result is achieved by the fact that a new highly labeled with tritium N-methyl-N-2-propynylbenzylamine of the formula I is obtained.

 The following is an example implementation of the invention.

Example. 10 mg of 5% Pd / BaSO _{4 was} placed in the reaction ampoule, kept in a tritium atmosphere for 30 min, then evacuated to a pressure of 0.1 Pa, 5 mg of pargyline was introduced into the ampoule, and a solution of 3 Ki of tritium water in 300 μl of dioxane was distilled into it and 20 μl of triethylamine. Tritium water was prepared immediately before the experiment by reducing 30 mg of palladium oxide in a mixture of 300 μl of dioxane and 20 μl of triethylamine with tritium gas at room temperature for 12 h with stirring (after this reaction, the mixture was frozen with liquid nitrogen and tritium was removed by vacuum at a pressure of 0.1 Pa). The reaction with tritium water was carried out at room temperature with stirring for 21 hours. Then, the ampoule was frozen with liquid nitrogen, vacuum and distilled tritium water and solvent in a special receiver. 3 ml of methanol was added to the residue, the solution was filtered, the catalyst was washed with methanol (3 × 3 ml). After removal of labile tritium by repeated evaporation with methanol (5x1 ml), the desired product was isolated by chromatographic methods. HPLC was carried out on a 10 × 250 mm column, Silasorb C ₁₈ , 13 μm, in a methanol-50 mm ammonium dihydrogen phosphate system (25: 75) (pH 2.8), eluent speed 2.0 ml / min, retention time 27.15 min, then on a 4x150 mm column, Kromasil l00C ₁₈ , 7 μm, in a methanol-50 mM ammonium dihydrogen phosphate system (15:85) (pH 2.8), eluent speed 0.8 ml / min, retention time 10, 79 minutes The yield of labeled drug is 5%, and molar radioactivity is 0.54 Ci / mmol.

 Thus, a new highly labeled tritium analogue of a physiologically active compound was obtained.

Claims (1)

Highly labeled tritium N-methyl-N-2-propynylbenzylamine of formula I